Comparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 TrialsComparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 Trials